Your browser doesn't support javascript.
loading
Biologic response modifiers in pediatric cancer.
Worth, L L; Jeha, S S; Kleinerman, E S.
Afiliação
  • Worth LL; Department of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Hematol Oncol Clin North Am ; 15(4): 723-40, ix, 2001 Aug.
Article em En | MEDLINE | ID: mdl-11676281
Biologic response modifiers are becoming an important addition to surgery, chemotherapy, and radiotherapy in the management of cancer. As this field of research grows and expands, more biologic response modifiers will be incorporated into therapeutic regimens. By stimulating the immune system to eradicate minimal residual disease, these agents may improve the disease-free and long-term survival rates of patients with a variety of malignancies. The challenge is to incorporate biologic response modifiers into the treatment armamentarium in ways that will maximize their tumorigenicity.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Acetilmuramil-Alanil-Isoglutamina / Fatores Imunológicos / Neoplasias Tipo de estudo: Prognostic_studies Idioma: En Revista: Hematol Oncol Clin North Am Ano de publicação: 2001 Tipo de documento: Article País de afiliação: Estados Unidos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Acetilmuramil-Alanil-Isoglutamina / Fatores Imunológicos / Neoplasias Tipo de estudo: Prognostic_studies Idioma: En Revista: Hematol Oncol Clin North Am Ano de publicação: 2001 Tipo de documento: Article País de afiliação: Estados Unidos